Board Member Bets Big on Redcare Pharmacy Amid Steep Decline

A significant insider transaction at Redcare Pharmacy has captured market attention as the company's shares continue their downward trajectory. Dr. Björn Söder, a member of the supervisory board, has made a substantial personal investment in the online pharmacy pioneer, acquiring shares worth approximately €128,000 during a period of extreme market pessimism.

Regulatory filings reveal that on November 11, 2025, Dr. Söder purchased Redcare Pharmacy shares at a price of €63.975 per unit, with the total transaction valued at €127,950. This move becomes particularly noteworthy given its timing—the purchase occurred when the stock was trading near its 52-week low, suggesting a high-ranking insider is committing personal funds precisely when investor sentiment appears most negative.

Examining the Steep Decline

The context surrounding this insider purchase highlights the severity of Redcare's recent performance challenges. The company's equity has been locked in a pronounced downtrend, having surrendered more than half its value since the beginning of the year. Recent trading sessions have been especially brutal, with the stock declining nearly 30% over the past month alone.

Current price levels around €62 represent a dramatic fall from the peak of €160 reached in December 2024, leaving shares trading more than 60% below their 52-week high.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

Key performance metrics illustrate the concerning trend:
* Monthly performance: -26.41%
* Year-to-date decline: -52.85%
* Distance from 52-week high: -61.25%

Intensifying Competitive Pressures

The broader online pharmacy sector continues to expand, yet competitive dynamics have grown increasingly fierce. Recent industry analysis indicates that certain competitors are outpacing market growth rates, capturing additional market share while others struggle to keep pace with overall sector development. In this heated battle for customer acquisition, Redcare Pharmacy faces challenges from both established rivals and emerging market entrants.

Market observers are now questioning whether this supervisory board member's substantial investment can potentially reverse the negative momentum, or if it represents merely a symbolic gesture during an extended period of selling pressure. The coming trading sessions will likely provide clearer indications of whether this insider confidence signals a potential turning point.